Jazz submits complete responses for Luvox
This article was originally published in Pharmaceutical Approvals Monthly
Jazz Pharmaceuticals announces FDA's acceptance of a complete response to an "approvable" letter for Luvox CR (fluvoxamine maleate extended-release capsules), setting a user fee date at December 22. The NDA seeks claims for treatment of obsessive compulsive disorder and social anxiety disorder. FDA also has accepted the submission of Solvay Pharmaceuticals' complete response to its approvable letter for Luvox immediate-release tablets, setting the action date at December 21. Jazz licensed U.S. marketing rights to Luvox CR and Luvox from Solvay in January. Jazz expects to launch Luvox CR in the U.S. during the first quarter of 2008. The firm had its initial public offering in May (1Pharmaceutical Approvals Monthly June 2007, p. 6)...
You may also be interested in...
Targanta may need to conduct additional clinical trials of its intravenous antibiotic oritavancin if FDA does not accept the company's use of a 15 percent noninferiority delta in its Phase III trial, according to the firm's initial public offering prospectus filed May 11 with the Securities & Exchange Commission.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.